BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Ermis F, Senocak Tasci E. New treatment strategies for hepatitis C infection. World J Hepatol 2015; 7(17): 2100-2109 [PMID: 26301052 DOI: 10.4254/wjh.v7.i17.2100] [Cited by in CrossRef: 19] [Cited by in F6Publishing: 16] [Article Influence: 2.7] [Reference Citation Analysis]
Number Citing Articles
1 Huynh T, Hu KQ. Direct acting antiviral-induced dynamic reduction of serum α fetoprotein in hepatitis C patients without hepatocellular carcinoma. Front Med 2019;13:658-66. [PMID: 31655955 DOI: 10.1007/s11684-019-0707-7] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
2 Blair W, Cox C. Current Landscape of Antiviral Drug Discovery. F1000Res 2016;5:F1000 Faculty Rev-202. [PMID: 26962437 DOI: 10.12688/f1000research.7665.1] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 2.8] [Reference Citation Analysis]
3 Buchanan-Hughes AM, Buti M, Hanman K, Langford B, Wright M, Eddowes LA. Health state utility values measured using the EuroQol 5-dimensions questionnaire in adults with chronic hepatitis C: a systematic literature review and meta-analysis. Qual Life Res 2019;28:297-319. [PMID: 30225787 DOI: 10.1007/s11136-018-1992-3] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 1.3] [Reference Citation Analysis]
4 Falla AM, Hofstraat SHI, Duffell E, Hahné SJM, Tavoschi L, Veldhuijzen IK. Hepatitis B/C in the countries of the EU/EEA: a systematic review of the prevalence among at-risk groups. BMC Infect Dis 2018;18:79. [PMID: 29433454 DOI: 10.1186/s12879-018-2988-x] [Cited by in Crossref: 47] [Cited by in F6Publishing: 44] [Article Influence: 11.8] [Reference Citation Analysis]
5 Ogbuagu O, Friedland G, Bruce RD. Drug interactions between buprenorphine, methadone and hepatitis C therapeutics. Expert Opinion on Drug Metabolism & Toxicology 2016;12:721-31. [DOI: 10.1080/17425255.2016.1183644] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 1.5] [Reference Citation Analysis]
6 Haider SA, Ahmad B, Ali S, Haider A, Bashir S, Mahmood N. Sofosbuvir and Ribavirin Combination Therapy Response in Various Hepatitis C Virus Genotypes in Peshawar, Khyber Pakhtunkhwa. Jundishapur J Microbiol 2020;13. [DOI: 10.5812/jjm.99625] [Reference Citation Analysis]
7 Jakobsen JC, Nielsen EE, Feinberg J, Katakam KK, Fobian K, Hauser G, Poropat G, Djurisic S, Weiss KH, Bjelakovic M, Bjelakovic G, Klingenberg SL, Liu JP, Nikolova D, Koretz RL, Gluud C. Direct-acting antivirals for chronic hepatitis C. Cochrane Database Syst Rev 2017;9:CD012143. [PMID: 28922704 DOI: 10.1002/14651858.CD012143.pub3] [Cited by in Crossref: 21] [Cited by in F6Publishing: 24] [Article Influence: 4.2] [Reference Citation Analysis]
8 Petruzziello A, Loquercio G, Sabatino R, Balaban DV, Ullah Khan N, Piccirillo M, Rodrigo L, di Capua L, Guzzo A, Labonia F, Botti G. Prevalence of Hepatitis C virus genotypes in nine selected European countries: A systematic review. J Clin Lab Anal 2019;33:e22876. [PMID: 30843304 DOI: 10.1002/jcla.22876] [Reference Citation Analysis]
9 Huynh T, Hu KQ. Excellent Safety and Sustained Virologic Response to Direct-Acting Antivirals Treatment in HCV-Infected Geriatric Patients: A Real-World Data. Dig Dis Sci 2021;66:1327-34. [PMID: 32405981 DOI: 10.1007/s10620-020-06286-3] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
10 Alavian SM, Hajarizadeh B, Bagheri Lankarani K, Sharafi H, Ebrahimi Daryani N, Merat S, Mohraz M, Mardani M, Fattahi MR, Poustchi H. Recommendations for the Clinical Management of Hepatitis C in Iran: A Consensus-Based National Guideline. Hepat Mon. 2016;16:e40959. [PMID: 27799966 DOI: 10.5812/hepatmon.guideline] [Cited by in Crossref: 42] [Cited by in F6Publishing: 36] [Article Influence: 7.0] [Reference Citation Analysis]
11 Dobler CC, Morgan RL, Falck-Ytter Y, Montori VM, Murad MH. Assessing the validity of surrogate endpoints in the context of a controversy about the measurement of effectiveness of hepatitis C virus treatment. BMJ Evid Based Med 2018;23:50-3. [PMID: 29595129 DOI: 10.1136/bmjebm-2017-110852] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
12 Jakobsen JC, Nielsen EE, Feinberg J, Katakam KK, Fobian K, Hauser G, Poropat G, Djurisic S, Weiss KH, Bjelakovic M, Bjelakovic G, Klingenberg SL, Liu JP, Nikolova D, Koretz RL, Gluud C. Direct-acting antivirals for chronic hepatitis C. Cochrane Database Syst Rev 2017;6:CD012143. [PMID: 28585310 DOI: 10.1002/14651858.CD012143.pub2] [Cited by in Crossref: 10] [Cited by in F6Publishing: 21] [Article Influence: 2.0] [Reference Citation Analysis]
13 Rezaee Zavareh MS, Alavian SM. Occult Hepatitis C Infection Should Be More Noticed With New Treatment Strategies. Hepat Mon. 2015;15:e33462. [PMID: 26834794 DOI: 10.5812/hepatmon.33462] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
14 Udina M, Navinés R, Egmond E, Oriolo G, Langohr K, Gimenez D, Valdés M, Gómez-Gil E, Grande I, Gratacós M, Kapczinski F, Artigas F, Vieta E, Solà R, Martín-Santos R. Glucocorticoid Receptors, Brain-Derived Neurotrophic Factor, Serotonin and Dopamine Neurotransmission are Associated with Interferon-Induced Depression. Int J Neuropsychopharmacol 2016;19:pyv135. [PMID: 26721949 DOI: 10.1093/ijnp/pyv135] [Cited by in Crossref: 21] [Cited by in F6Publishing: 20] [Article Influence: 3.5] [Reference Citation Analysis]
15 Aby E, Jimenez MA, Grotts JF, Agopian V, French SW, Busuttil RW, Saab S. Diminishing Use of Liver Biopsy among Liver Transplant Recipients for Hepatitis C. J Clin Transl Hepatol 2017;5:197-202. [PMID: 28936400 DOI: 10.14218/JCTH.2016.00073] [Cited by in Crossref: 1] [Article Influence: 0.2] [Reference Citation Analysis]
16 Jakobsen JC, Nielsen EE, Feinberg J, Fobian K, Katakam KK, Hauser G, Poropat G, Djurisic S, Weiss KH, Bjelakovic M, Bjelakovic G, Klingenberg SL, Liu JP, Nikolova D, Koretz RL, Gluud C, Jakobsen JC. Direct-acting antivirals for chronic hepatitis C. Cochrane Database of Systematic Reviews. Chichester: John Wiley & Sons, Ltd; 1996. [DOI: 10.1002/14651858.cd012143] [Cited by in Crossref: 5] [Article Influence: 0.8] [Reference Citation Analysis]
17 Mohamed AA, Eljaky AM, Abdelsameea EM, Fouad TR, El-ezawy HEM. Prevalence and effect of occult hepatitis C infection in patients with persistent liver enzyme elevation after achieving 24 weeks of sustained virological response. Egypt J Intern Med 2019;31:288-91. [DOI: 10.4103/ejim.ejim_24_19] [Reference Citation Analysis]
18 Than NN, Ghazanfar A, Hodson J, Tehami N, Coldham C, Mergental H, Manas D, Shah T, Newsome PN, Reeves H, Shetty S. Comparing clinical presentations, treatments and outcomes of hepatocellular carcinoma due to hepatitis C and non-alcoholic fatty liver disease. QJM 2017;110:73-81. [PMID: 27634970 DOI: 10.1093/qjmed/hcw151] [Cited by in Crossref: 5] [Cited by in F6Publishing: 11] [Article Influence: 1.0] [Reference Citation Analysis]
19 Petruzziello A, Loquercio G, Sabatino R, Balaban DV, Ullah Khan N, Piccirillo M, Rodrigo L, di Capua L, Guzzo A, Labonia F, Botti G. Prevalence of Hepatitis C virus genotypes in nine selected European countries: A systematic review. J Clin Lab Anal. 2019;33:e22876. [PMID: 30843304 DOI: 10.1002/jcla.22876] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 3.7] [Reference Citation Analysis]
20 Chaillon A, Mehta SR, Hoenigl M, Solomon SS, Vickerman P, Hickman M, Skaathun B, Martin NK. Cost-effectiveness and budgetary impact of HCV treatment with direct-acting antivirals in India including the risk of reinfection. PLoS One 2019;14:e0217964. [PMID: 31170246 DOI: 10.1371/journal.pone.0217964] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]